|Chemical and physical data|
|Molar mass||446.347 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
SB-399885 is a drug which is used in scientific research. It acts as a potent, selective and orally active 5-HT6 receptor antagonist, with a Ki of 9.0nM. SB-399885 and other 5-HT6 antagonists show nootropic effects in animal studies, as well as antidepressant and anxiolytic effects which are comparable to and synergistic with drugs such as imipramine and diazepam, and have been proposed as potential novel treatments for cognitive disorders such as schizophrenia and Alzheimer's disease.
- Perez-García, G; Meneses, A (2005). "Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task". Pharmacology Biochemistry and Behavior. 81 (3): 673–82. doi:10.1016/j.pbb.2005.05.005. PMID 15964617.
- Hirst, WD; Stean, TO; Rogers, DC; Sunter, D; Pugh, P; Moss, SF; Bromidge, SM; Riley, G; et al. (2006). "SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models". European Journal of Pharmacology. 553 (1–3): 109–19. doi:10.1016/j.ejphar.2006.09.049. PMID 17069795.
- Wesołowska, A; Nikiforuk, A (2007). "Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression". Neuropharmacology. 52 (5): 1274–83. doi:10.1016/j.neuropharm.2007.01.007. PMID 17320917.
- Wesołowska, A (2008). "The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors". European Journal of Pharmacology. 580 (3): 355–60. doi:10.1016/j.ejphar.2007.11.022. PMID 18096153.
- Wesołowska, A; Nikiforuk, A (2008). "The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats". European Journal of Pharmacology. 582 (1–3): 88–93. doi:10.1016/j.ejphar.2007.12.013. PMID 18234190.
- Li, Z; Huang, M; Prus, AJ; Dai, J; Meltzer, HY (2007). "5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus". Brain Research. 1134 (1): 70–8. doi:10.1016/j.brainres.2006.11.060. PMID 17207474.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|